This company is no longer active
Immune Pharmaceuticals Valuation
Is IMNP.Q undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Share Price vs Fair Value
What is the Fair Price of IMNP.Q when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate IMNP.Q's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate IMNP.Q's fair value to establish if it is undervalued.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IMNP.Q?
Other financial metrics that can be useful for relative valuation.
| What is IMNP.Q's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$401.99k |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | n/a |
| PEG Ratio | n/a |
Ratio vs Peers
How does IMNP.Q's Ratio compare to its peers?
| Company | Estimated Growth | Market Cap | |
|---|---|---|---|
| Peer Average | n/a | ||
IMNP.Q Immune Pharmaceuticals | n/a | n/a | US$402.0k |
Price to Earnings Ratio vs Industry
How does IMNP.Q's PE Ratio compare vs other companies in the US Biotechs Industry?
Ratio vs Fair Ratio
What is IMNP.Q's Ratio compared to its Fair Ratio? This is the expected Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current Ratio | |
| Fair Ratio | n/a |
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?